Karyopharm delays debt payment; Amgen explores expanded use for Imdelltra
Cash-strapped Karyopharm Therapeutics has secured additional time to meet its $15.8 million debt obligation, which was due on September 9, by reaching a deal with creditors that extends the deadline until October 15. As part of the agreement, Karyopharm issued $20 million in convertible stock and will use this reprieve to explore strategic options or raise capital. Amgen reported positive results from a Phase 3 trial showing its drug Imdelltra combined with AstraZeneca’s Imfinzi extended survival for patients with first-line extensive small-cell lung cancer. This could lead to expanded approval, significantly increasing the drug's market potential beyond its current indication as a second-line treatment. Meanwhile, Evommune and BridgeBio Oncology Therapeutics faced setbacks in their clinical trials.
Tickers: $AMGN $AZN $BBOT $EVMN $KPTI